Actinogen Medical (Australia) Performance
| ACW Stock | 0.03 0 3.85% |
The firm shows a Beta (market volatility) of -1.69, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Actinogen Medical are expected to decrease by larger amounts. On the other hand, during market turmoil, Actinogen Medical is expected to outperform it. At this point, Actinogen Medical has a negative expected return of -0.53%. Please make sure to confirm Actinogen Medical's maximum drawdown, potential upside, kurtosis, as well as the relationship between the value at risk and skewness , to decide if Actinogen Medical performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Actinogen Medical has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:2 | Last Split Date 2013-12-03 |
| Begin Period Cash Flow | 8.5 M |
Actinogen |
Actinogen Medical Relative Risk vs. Return Landscape
If you would invest 4.10 in Actinogen Medical on August 31, 2024 and sell it today you would lose (1.40) from holding Actinogen Medical or give up 34.15% of portfolio value over 90 days. Actinogen Medical is producing return of less than zero assuming 4.7363% volatility of returns over the 90 days investment horizon. Simply put, 42% of all stocks have less volatile historical return distribution than Actinogen Medical, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Actinogen Medical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Actinogen Medical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Actinogen Medical, and traders can use it to determine the average amount a Actinogen Medical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1119
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ACW |
Estimated Market Risk
| 4.74 actual daily | 42 58% of assets are more volatile |
Expected Return
| -0.53 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Actinogen Medical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Actinogen Medical by adding Actinogen Medical to a well-diversified portfolio.
Actinogen Medical Fundamentals Growth
Actinogen Stock prices reflect investors' perceptions of the future prospects and financial health of Actinogen Medical, and Actinogen Medical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Actinogen Stock performance.
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.45 | ||||
| Profit Margin | (1.31) % | ||||
| Operating Margin | (0.18) % | ||||
| Current Valuation | 71.02 M | ||||
| Shares Outstanding | 3.08 B | ||||
| Price To Book | 4.07 X | ||||
| Price To Sales | 8.38 X | ||||
| Revenue | 9.93 M | ||||
| Gross Profit | 4.89 M | ||||
| EBITDA | (12.92 M) | ||||
| Net Income | (13.04 M) | ||||
| Cash And Equivalents | 7.18 M | ||||
| Total Debt | 319.07 K | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (16.95 M) | ||||
| Earnings Per Share | (0.01) X | ||||
| Total Asset | 21.31 M | ||||
| Retained Earnings | (81.74 M) | ||||
About Actinogen Medical Performance
Assessing Actinogen Medical's fundamental ratios provides investors with valuable insights into Actinogen Medical's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Actinogen Medical is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Actinogen Medical is entity of Australia. It is traded as Stock on AU exchange.Things to note about Actinogen Medical performance evaluation
Checking the ongoing alerts about Actinogen Medical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Actinogen Medical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Actinogen Medical generated a negative expected return over the last 90 days | |
| Actinogen Medical has some characteristics of a very speculative penny stock | |
| Actinogen Medical has high historical volatility and very poor performance | |
| Actinogen Medical has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 9.93 M. Net Loss for the year was (13.04 M) with profit before overhead, payroll, taxes, and interest of 4.89 M. | |
| Actinogen Medical has accumulated about 7.18 M in cash with (16.95 M) of positive cash flow from operations. | |
| Roughly 16.0% of the company shares are held by company insiders |
- Analyzing Actinogen Medical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Actinogen Medical's stock is overvalued or undervalued compared to its peers.
- Examining Actinogen Medical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Actinogen Medical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Actinogen Medical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Actinogen Medical's stock. These opinions can provide insight into Actinogen Medical's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Actinogen Stock Analysis
When running Actinogen Medical's price analysis, check to measure Actinogen Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actinogen Medical is operating at the current time. Most of Actinogen Medical's value examination focuses on studying past and present price action to predict the probability of Actinogen Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actinogen Medical's price. Additionally, you may evaluate how the addition of Actinogen Medical to your portfolios can decrease your overall portfolio volatility.